Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philippe Armand, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Philippe Armand and Jennifer Crombie.
Connection Strength

4.319
  1. Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm. J Clin Oncol. 2020 10 20; 38(30):3565-3574.
    View in: PubMed
    Score: 0.937
  2. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment. Surg Oncol Clin N Am. 2020 Jan; 29(1):115-125.
    View in: PubMed
    Score: 0.897
  3. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment. Hematol Oncol Clin North Am. 2019 08; 33(4):575-585.
    View in: PubMed
    Score: 0.859
  4. The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders. Curr Hematol Malig Rep. 2019 02; 14(1):11-21.
    View in: PubMed
    Score: 0.842
  5. A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
    View in: PubMed
    Score: 0.239
  6. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
    View in: PubMed
    Score: 0.213
  7. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
    View in: PubMed
    Score: 0.057
  8. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
    View in: PubMed
    Score: 0.056
  9. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
    View in: PubMed
    Score: 0.056
  10. Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? Hemasphere. 2019 Oct; 3(5):e284.
    View in: PubMed
    Score: 0.054
  11. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 09 12; 134(11):860-866.
    View in: PubMed
    Score: 0.054
  12. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.
    View in: PubMed
    Score: 0.054
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.